Regeneron and Sanofi announced Phase 3 trial results for itepekimab, a potential COPD treatment for former smokers. AERIFY-1 met its primary endpoint, showing a statistically significant 27% reduction in moderate to severe exacerbations at week 52. However, AERIFY-2, a second Phase 3 trial, did not achieve the same primary endpoint, despite demonstrating a benefit earlier in the study. Itepekimab’s safety profile remained consistent with previous trials.

The success of AERIFY-1 offers a potential new therapeutic avenue for former smokers with COPD, a population often facing limited treatment options after exhausting standard inhaled therapies. The contrasting results between AERIFY-1 and AERIFY-2 raise crucial questions about the underlying mechanisms of itepekimab’s action and the influence of external factors, such as the COVID-19 pandemic, on exacerbation rates during the trial period. Further investigation is necessary to understand these discrepancies and determine the optimal patient population for this therapy.

In AERIFY-1, itepekimab administered every two or four weeks resulted in a 27% and 21% reduction in moderate to severe exacerbations at week 52, respectively. AERIFY-2 showed an 18% and 21% reduction at week 24 for the bi-weekly and monthly dosing, but this benefit diminished by week 52. The lower-than-anticipated exacerbation rates across both trials, potentially influenced by the COVID-19 pandemic, may have affected the statistical power of the studies. Adverse events were comparable between itepekimab and placebo groups.

The AERIFY-1 results provide a foundation for potential regulatory discussions and further clinical development of itepekimab for COPD. While the AERIFY-2 results introduce complexity, the combined data from both trials will be essential for refining the understanding of itepekimab’s role in treating COPD. Further research and analysis, including presentations at future medical meetings, will be crucial to determine the future direction of itepekimab development for this challenging disease.

Source link: https://www.globenewswire.com/news-release/2025/05/30/3090814/0/en/Itepekimab-Met-Primary-Endpoint-in-One-of-Two-Chronic-Obstructive-Pulmonary-Disease-COPD-Phase-3-Trials.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.